Enrollment has begun in two, 600-subject Phase III trials of rifaximin for treatment of non-constipation irritable bowel syndrome. The studies, which will include 180 sites in Canada and the U.S., will examine how many patients get relief of IBS symptoms for at least two weeks during the first four weeks of a 10-week follow up period after 14 days of receiving rifaximin.

Related Summaries